Tests nitrate tablets in people with normal tension glaucoma

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 50-90 with normal tension glaucoma that keeps getting worse despite eye-drop treatment. It tests a long-acting nitrate tablet (Ismox 20 mg).

Age

50-90 years

Sex

All sexes

Disease stage

Previously diagnosed normal tension glaucoma that has worsened over follow-up scans and visual field tests. At least two earlier OCT scans and visual field tests are needed. Nerve fibre layer thickness is under 75 micrometres, or thin in two sectors, and the visual field mean defect is at least 5 dB.

Earlier treatment

Must use at least two active substances as eye-drop treatment for glaucoma. Must never have had nitrate heart medicines.

Main reasons for not taking part

• Allergy to isosorbide mononitrate or other organic nitrates
• Low blood pressure (systolic below 90 mmHg), shock, heart failure, heart attack, heart muscle disease or heart valve defect
• Eye pressure above 21 mmHg during the last year
• Using erectile dysfunction medicines such as sildenafil, tadalafil or vardenafil
• Underactive thyroid, severe anaemia, low blood volume, severe kidney or liver failure, or other serious illness such as cancer under treatment

The registry criteria, word for word

What the trial wants to find out

Selvittää tehostaako pitkävaikutteisen peroraalisen nitraatin (isosorbidi-5-mononitraatti; Ismox 20 mg) käyttö näköhermonnystyn verenkiertoa matalapaineglaukoomassa. Selvittää nitraattien vaikutusta matalapaineglaukooman hoidossa muun käytössä olevan paikallislääkityksen rinnalla. Tarkastella nitraattien anatomista ja toiminnallista vastetta hyödyntäen kuvantamisessa muun muassa näköhermonnystyn valokerroskuvausta, sekä näkökenttätutkimusta.